#United States #Class Action #Radnor #Kessler Topaz Meltzer #Neumora Therapeutics

Kessler Topaz Meltzer & Check, LLP's Alert to Neumora Therapeutics Investors

In an important announcement for investors of Neumora Therapeutics, Inc. (NASDAQ: NMRA), the law firm Kessler Topaz Meltzer & Check, LLP has issued a reminder about a class action lawsuit that is currently underway. This legal action concerns those who purchased or acquired Neumora common stock in connection with the company's initial public offering (IPO) around September 15, 2023. The deadline for investors to file as lead plaintiffs is April 7, 2025.

Overview of the Lawsuit

The lawsuit against Neumora Therapeutics claims that the company’s Offering Documents, which were provided to investors during its IPO, included materially false and misleading statements. Specifically, it is alleged that Neumora was compelled to adjust the inclusion criteria for its Phase Three program, necessitating that patients with moderate to severe major depressive disorder (MDD) be added to the tests in order to demonstrate a statistically significant treatment improvement with Navacaprant. This raised serious questions about the authenticity of the claims made to investors regarding Neumora's drug efficacy.

Moreover, the complaint argues that the statistical data from the Phase Two trials were inadequate. Critical factors such as the patient population's size and the gender ratio within that population were allegedly not sufficient to make accurate predictions regarding the outcomes of the subsequent KOASTAL-1 study.

The Role of the Lead Plaintiff

For investors seeking to take action, Kessler Topaz Meltzer & Check, LLP emphasizes the importance of establishing a lead plaintiff to represent the class. The lead plaintiff is typically a member of the group with the largest financial interest and will guide the representation of all class members throughout the litigation process. This individual will have the responsibility of selecting legal counsel to advocate on behalf of the class. It is crucial to note that not being appointed as the lead plaintiff doesn't affect an investor's ability to receive a portion of any potential recovery from the lawsuit.

How to Participate

Investors who have faced losses related to Neumora are urged to reach out to Kessler Topaz Meltzer & Check, LLP to gather more information about the process of joining the class action. Interested parties can visit their website or contact attorney Jonathan Naji directly via telephone or email. The law firm highlights that individuals affected by the alleged misconduct should act swiftly, as the deadline to register as a lead plaintiff draws near.

Kessler Topaz Meltzer & Check, LLP is known for advocating for investors and holds a strong reputation in prosecuting class actions aimed at addressing cases of fraud and corporate misconduct. Their dedication to fighting for the rights of investors, consumers, and employees can provide those affected by the current situation with the expertise and support they need.

Contact Information

Investors who wish to explore their options or seek further assistance can follow these contact details:
- Phone: (484) 270-1453
- Email: [email protected]
- Website: www.ktmc.com

As the situation surrounding Neumora Therapeutics continues to develop, being proactive as an investor may prove vital. Stay informed and engaged to ensure your rights are safeguarded during these challenging times.